in order to assess whether different doses and/or plasma levels of almitrine bismesylate ( abm ) could induce preferential effects on ventilation or on lung perfusion , we performed a single-blind placebo-controlled study of abm treatment with different dosages ( 0.75 , 1.5 and 2.25 mg.kg-1 single oral dose ) in 26 patients suffering from chronic obstructive pulmonary disease ( copd ) .
C0024109
lung
C0024117
chronic obstructive pulmonary disease